These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35439421)

  • 21. Update on systemic therapy of advanced non-small-cell lung cancer.
    Cufer T; Knez L
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors.
    Spagnuolo A; Maione P; Gridelli C
    Expert Opin Emerg Drugs; 2018 Sep; 23(3):231-241. PubMed ID: 30251885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis.
    Murugesan S; Murugesan J; Palaniappan S; Palaniappan S; Murugan T; Siddiqui SS; Loganathan S
    Curr Cancer Drug Targets; 2021; 21(1):55-69. PubMed ID: 33038912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
    Minguet J; Smith KH; Bramlage P
    Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 10 years into the resurgence of covalent drugs.
    De Vita E
    Future Med Chem; 2021 Jan; 13(2):193-210. PubMed ID: 33275063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.
    Agarwal SM; Pal D; Gupta M; Saini R
    Curr Cancer Drug Targets; 2017; 17(7):617-636. PubMed ID: 28359250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements.
    Yang J; Tabuchi Y; Katsuki R; Taki M
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
    Golding B; Luu A; Jones R; Viloria-Petit AM
    Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR-directed therapies to treat non-small-cell lung cancer.
    Ho C; Laskin J
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer.
    Qin H; Patel MR
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
    Kujtan L; Subramanian J
    Expert Rev Anticancer Ther; 2019 Jul; 19(7):547-559. PubMed ID: 30913927
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
    Lee DH
    Pharmacol Ther; 2017 Jun; 174():1-21. PubMed ID: 28167215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy.
    Das D; Hong J
    Mini Rev Med Chem; 2020; 20(17):1732-1753. PubMed ID: 32400331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.
    Serritella AV; Bestvina CM
    Thorac Surg Clin; 2020 May; 30(2):137-146. PubMed ID: 32327172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
    Tomassi S; Lategahn J; Engel J; Keul M; Tumbrink HL; Ketzer J; Mühlenberg T; Baumann M; Schultz-Fademrecht C; Bauer S; Rauh D
    J Med Chem; 2017 Mar; 60(6):2361-2372. PubMed ID: 28225269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in irreversible kinase inhibitors.
    Gilbert AM
    Pharm Pat Anal; 2014 Jul; 3(4):375-86. PubMed ID: 25291312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
    Halliday PR; Blakely CM; Bivona TG
    Curr Oncol Rep; 2019 Feb; 21(3):21. PubMed ID: 30806814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.